Description
This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications (ANDAs). This guidance highlights common, recurring deficiencies that may lead to a delay in the approval of an ANDA. It also makes recommendations to applicants on how to avoid these deficiencies with the goal of minimizing the number of review cycles necessary for approval.
Scope & Applicability
Product Classes
10topic of the guidance document
products requiring endotoxin specifications
endotoxin specification requirements
Products combining drug, device, or biological constituents; Generally recommended for Enhanced Documentation; Requires 14971-based framework incorporating ICH Q9; A drug-device combination where the device constituent part detects ingestion.
dissolution acceptance criteria requirements
dissolution acceptance criteria requirements
Failure to establish appropriate CQAs of the proposed generic drug product
The subject of the temporary compounding policies.; Injectable drugs subject to temporary compounding policies
The drug product identified by the applicant for comparison; Comparison of ANDA product to RLD for pH adjuster differences
Reference Listed Drug used as the basis for an ANDA submission.
Stakeholders
5entity submitting marketing applications
Governs top dose in clinical studies
Drug Master File holders included in the term 'manufacturers and applicants'.
new facilities added by the DMF holder
ANDA applicant first to file a substantially complete ANDA with a paragraph IV certification; The first ANDA applicant to submit a paragraph IV certification
Regulatory Context
Attributes
6Modulation of topical product strength to support IVPT sensitivity
MVD calculations in endotoxin testing
quality attributes of intermediates
Physical state of the API that must be consistently manufactured.
Incentive granted to certain ANDA applicants
Exclusivity granted to the first applicant
Identified Hazards
Hazards
4identity and level of any impurities and contaminants
microbiological contamination risk in bulk solution
Ability of a compound to induce point mutations
safety considerations to minimize medication errors; minimize medication errors through label design
Related CFR Sections (9)
- 21CFR314.96§ 314.96 Amendments to an unapproved ANDA.
(a) ANDA.Read full regulation →
- 21CFR3.2§ 3.2 Definitions.
For the purpose of this part:Read full regulation →
- 21CFR314.50§ 314.50 Content and format of an NDA.
NDAs and supplements to approved NDAs are required to be submitted in the form and contain the information, as appropriate for the particular submission, required under this section. Three copies of the NDA are required: An archival copy, a review copy, and a field copy. An NDA for a new chemical enRead full regulation →
- 21CFR314.94§ 314.94 Content and format of an ANDA.
ANDAs are required to be submitted in the form and contain the information required under this section. Three copies of the ANDA are required, an archival copy, a review copy, and a field copy. FDA will maintain guidance documents on the format and content of ANDAs to assist applicants in their prepRead full regulation →
- 21CFR314.3§ 314.3 Definitions.
(a) The definitions and interpretations contained in section 201 of the Federal Food, Drug, and Cosmetic Act apply to those terms when used in this part and part 320 of this chapter .Read full regulation →
- 21CFR314.420§ 314.420 Drug master files.
(a) A drug master file is a submission of information to the Food and Drug Administration by a person (the drug master file holder) who intends it to be used for one of the following purposes: To permit the holder to incorporate the information by reference when the holder submits an investigationalRead full regulation →
- 21CFR314.99§ 314.99 Other responsibilities of an applicant of an ANDA.
(a) An applicant must comply with the requirements of § 314.65 regarding withdrawal by the applicant of an unapproved ANDA and § 314.72 regarding a change in ownership of an ANDA.Read full regulation →
- 21CFR314.95§ 314.95 Notice of certification of invalidity, unenforceability, or noninfringement of a patent.
(a) Notice of certification. For each patent that claims the listed drug or that claims a use for such listed drug for which the applicant is seeking approval and for which the applicant submits a paragraph IV certification, the applicant must send notice of such certification by registered or certiRead full regulation →
- 21CFR314.107§ 314.107 Date of approval of a 505(b)(2) application or ANDA.
(a) General. A drug product may be introduced or delivered for introduction into interstate commerce when the 505(b)(2) application or ANDA for the drug product is approved. A 505(b)(2) application or ANDA for a drug product is approved on the date FDA issues an approval letter under § 314.105 for tRead full regulation →
Related Warning Letters (4)
- 2025-03-18
CGMP/Finished Pharmaceutical/Adulterated
Advanced Pharmaceutical Technology
- 2024-08-27
CGMP/Drugs/Adulterated
EyePoint Pharmaceuticals, Inc.
- 2024-08-06
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
Omega Tech Labs LLC
- 2021-06-29
Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)
Aquavit Pharmaceuticals, Inc
See Also (8)
- Guidance for Industry 180-Day Exclusivity: Questions and Answers (Status: Draft)
- Cover Letter Attachments for Controlled Correspondences and ANDA Submissions: Guidance for Industry (Status: Final)
- ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs: Guidance for Industry (Status: Final)
- Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications (Status: Final)
- Rheumatoid Arthritis: Developing Drug Products for Treatment (Status: Draft)
- Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry: Guidance for Industry (Status: Final)
- Current Good Manufacturing Practice Requirements for Combination Products: Guidance for Industry and FDA Staff (Status: Final)
- Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry (Status: Draft)